Description:
Companion diagnostics are revolutionizing pharmaceutical development and treatment, particularly in oncology. By identifying patients with specific biomarkers or disease-specific therapeutic targets, companion diagnostics significantly improve clinical success rates and patient outcomes. They also reduce costs by pinpointing the patient population most likely to benefit from a therapy and excluding those for whom the therapy would be ineffective, a critical advantage given the high cost of many new cancer treatments.
The medical industry is undergoing significant transition, with increasing demand for advanced medical technology products driven by an aging population. Companion diagnostics play a crucial role in delivering cost-effective and efficient healthcare. This comprehensive report, Companion Diagnostics in the COVID-19 Era, provides essential data and resources for understanding the market for tests aligned with pharmaceutical treatments. Discover market size, leading players, regulatory changes, and the impact of COVID-19 on the sector.
Market Insights:
- COVID-19 Impact on Companion Diagnostics: Analysis of current market conditions and future prospects.
- Top Performing Targeted Therapies in Oncology: Based on 2019 sales.
- FDA Cleared/Approved Companion Diagnostic Tests: Data from 2010-2020.
- Global In Vitro Companion Diagnostic (CDx) Market: Projections from 2019-2024.
Regulatory Overview:
- FDA Regulatory Changes: Shifts in CDx regulation and drug classification labeling.
- FDA Approved Companion Diagnostics: Detailed overview for NSCLC patients with specific genetic mutations.
- EU Regulatory Guidance: Latest developments and guidelines for companion diagnostics in Europe.
Competitive Analysis:
- Companies Offering Companion and Complementary Diagnostics: Analysis by therapeutic area, including autoimmune disorders, cardiology, hematology, infectious diseases (including COVID-19), and neurology.
- Deep Dives into the CDx Market: Comprehensive data on the value and distribution of commercialized targeted therapies and companion diagnostics by cancer type, drug class, and technique.
Market Segmentation:
- Estimated Value of Non-Oncology Companion Diagnostics: Distribution by cancer type (2019).
- Commercialized Targeted Therapies Revenues: Comparison with companion diagnostic market value from 2015-2019.
- Global CDx Market by Region: Breakdown for the US, EU, Asia, and Rest of the World (2019-2024).
Technological Advancements:
Emerging technologies are driving companion diagnostic research, discovery, development, and commercialization, leading to an increase in exploratory studies and clinical applications in personalized medicine. Novel biomarkers and companion diagnostics are transforming healthcare from a one-size-fits-all approach to a personalized model.
For further details and to purchase directly, please contact us.
Sample Report: A sample is available as a PDF upon request.
Table: Global CDx Market, by Region, 2019-2024 ($ millions)
| Region | 2019 | 2024 | CAGR 2019-2024 |
| United States | $XX Million | $XX Million | XX% |
| Europe | $XX Million | $XX Million | XX% |
| Japan | $XX Million | $XX Million | XX% |
| China | $XX Million | $XX Million | XX% |
| Rest of World | $XX Million | $XX Million | XX% |
| Global | $XX Million | $XX Million | XX% |
Source: Kalorama Information
